11 Result(s)
within
Paolo Vigneri
Oncology
-
Article
Open AccessStandardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study
Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and Outcome Study for CML (EUTOS) explored the...
-
Article
Open AccessImpact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy
Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::ABL1 have a faster molecular response to therapy compared to patients expressing e13a2. To explore the reason for ...
-
Article
Open AccessThe prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer
In breast cancer (BC), recurrent fusion genes of estrogen receptor alpha (ESR1) and AKAP12, ARMT1 and CCDC170 have been reported. In these gene fusions the ligand binding domain of ESR1 has been replaced by the t...
-
Article
Open AccessDetection of tumor-derived extracellular vesicles in plasma from patients with solid cancer
Extracellular vesicles (EVs) are actively secreted by cells into body fluids and contain nucleic acids of the cells they originate from. The goal of this study was to detect circulating tumor-derived EVs (ctEV...
-
Chapter
Biomarkers
In the era of personalized medicine, biomarkers represent an irreplaceable tool for cancer screening, diagnosis, and management. As molecular biology techniques rapidly improve, several potential biomarkers ha...
-
Article
Open AccessNext-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
BCR-ABL1 kinase domain (KD) mutation status is considered to be an important element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do not achieve an optimal response to tyrosine ...
-
Article
Open AccessNon ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory hematological, cytogenetic ...
-
Article
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia
To assess the impact of BCR-ABL kinase domain mutations on dasatinib response in elderly chronic myeloid leukemia (CML) patients, we analyzed the outcome of 76 individuals aged >60 affected by imatinib-resista...
-
Article
Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy
-
Article
Open AccessIRF5 promotes the proliferation of human thyroid cancer cells
Interferon Regulatory Factor 5 is a transcription factor that regulates the expression of genes involved in the response to viral infection and in the stimulation of the immune system. Moreover, multiple studi...
-
Article
Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor
The Hepatocyte Growth Factor (HGF) and its receptor Met are physiological regulators of cell migration. HGF and Met have also been implicated in tumor progression and metastasis. We show here that the tyrosine...
